SOURCE: Barrier Therapeutics, Inc.

October 25, 2006 16:00 ET

Barrier Therapeutics to Present at the Susquehanna Emerging Trends Conference

PRINCETON, NJ -- (MARKET WIRE) -- October 25, 2006 -- Barrier Therapeutics, Inc. (NASDAQ: BTRX), a pharmaceutical company developing and commercializing products in the field of dermatology, today announced that Geert Cauwenbergh, Ph.D., Chief Executive Officer is scheduled to present to the investment community at the Susquehanna Emerging Trends Conference.

The conference will be held at The Peninsula Hotel in New York on November 1, 2006. Dr. Cauwenbergh is scheduled to present on Wednesday, November 1st, at 12:30 pm Eastern Standard Time.

The presentation will be available live via a webcast that can be accessed through Barrier Therapeutics' corporate website at:

About Barrier Therapeutics, Inc.

Barrier Therapeutics, Inc. is a pharmaceutical company focused on the discovery, development and commercialization of pharmaceutical products in the field of dermatology. Barrier Therapeutics currently markets three pharmaceutical products in the United States: Xolegel™ (ketoconazole, USP) Gel, 2%, Vusion™ (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment and Solagé® (mequinol 2.0%, tretinoin 0.01%) Topical Solution. Barrier has other product candidates in various stages of clinical development for the treatment of onychomycosis, psoriasis, acne, and fungal infections. The Company is headquartered in Princeton, New Jersey and has wholly owned subsidiaries in Geel, Belgium and Ontario, Canada.

Contact Information

  • Contacts:
    Barrier Therapeutics, Inc.
    Anne M. VanLent

    Noonan Russo
    Matt Haines